Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.

Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC₅₀s of 43.6 and 40.8 pM for human and marmoset IL-1β. Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15.  [Content Brief]

  . Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7(6):1151-60.  [Content Brief]